Advanced Bioaerosols Technology Core

项目摘要/摘要-先进的生物气溶胶技术核心 先进生物气溶胶技术核心(ABTC)将开发一套全面的创新 改进流感病毒气雾剂的采样、分离、培养和表征技术，以 启用新的分析能力，以支持U19研究项目目标。先进的技术 通过ABTC开发的将在每个单独的研究项目中使用，以产生更有效的结果 通过结合有效的环境采样评估空气传播和传染性的研究 感染病毒在临床环境中的大小依赖分布，以及高分辨率个体 呼气采样，以阐明准确传输建模所需的基本源项。 ABTC团队将利用生物工程、生物气溶胶系统工程和 呼吸道病毒学为先进的生物气溶胶分析开发5项相互关联的技术。在《目标1》中，一组 将开发一系列紧凑型仪器，用于收集和并行基于大小的环境分馏 环境气雾剂，以便在拟议的临床研究期间能够对空气传播的病毒进行分布式监测。在……里面 目标2，采用独特的呼气采样技术的第二台气溶胶采样仪将是 开发的目的是提供高分辨率的气溶胶分级和收集，使我们能够评估可行和 个人捐献者在狭窄的粒度范围内释放的非感染性病毒。增强感染力 对于样本病毒颗粒的表征，一种合成粘液水凝胶将作为一种新的 环境采样器的样本目标，提供改进的病毒捕获和细胞培养，大大改进 下游传染性分析的病毒捕获和生存能力。一项数字化细胞培养阵列技术将被 在AIM 4中开发，能够直接隔离呼气捕获的单个气雾剂颗粒 采样器，并允许我们评估活的和非感染的病毒单位的分布和聚集在 单粒子分辨率。ABTC团队还将开发一种优化的细胞系，用于 用研制的仪器对采集的病毒进行分析，以加强传染性评估。核心将会 通过一套验证开发的气溶胶采样、捕获、隔离、培养和分析技术 在与拟议的U19研究项目整合之前，对雪貂进行研究，并将执行所需的分析 使用临床样本支持RP1和RP2的目标。ABTC研究工作的结果将产生 加强我们对流感空气生物学的了解所需的仪器和技术，来自 用于评价环境中感染颗粒分布的临界源项的确定， 支持流感传播建模、风险分析和缓解方面的重大改进，同时 为增进我们对其他呼吸道病毒大流行威胁的了解做出了重要贡献。

Project Summary/Abstract – Advanced Bioaerosol Technology Core The Advanced Bioaerosol Technology Core (ABTC) will develop a comprehensive suite of innovative technologies for improved sampling, fractionation, culture, and characterization of influenza virus aerosols to enable new analytical capabilities in support of the U19 research project goals. The advanced technologies developed through the ABTC will be employed within each individual research project to yield more effective studies of airborne transmission and infectivity through a combination of efficient ambient sampling to evaluate size-dependent distributions of infective virus within the clinical environment, and high-resolution individual exhaled breath sampling to elucidate the fundamental source terms needed for accurate transmission modeling. The ABTC team will leverage expertise across the fields of bioengineering, bioaerosol system engineering, and respiratory virology to develop 5 interconnected technologies for advanced bioaerosol analysis. In Aim 1, a set of compact instruments will be developed for the collection and parallel size-based fractionation of ambient environmental aerosols to enable distributed monitoring of airborne virus during the proposed clinical studies. In Aim 2, a second aerosol sampling instrument employing a unique exhaled breath sampling technology will be developed to provide high resolution aerosol fractionation and collection, allowing us to evaluate both viable and non-infective virus emission from individual donors across narrow particle size ranges. To enhance infectivity characterization for sampled virus particles, a synthetic mucus hydrogel will be advanced in Aim 3 as a novel sample target for the environmental sampler, providing improved virus capture and cell culture, greatly improving virus capture and viability for downstream infectivity assays. A digital cell culture array technology will be developed in Aim 4, enabling the direct isolation of individual aerosol particles captured by the exhaled breath sampler, and allowing us to evaluate distribution and clustering of both viable and non-infective virus units at single particle resolution. The ABTC team will also develop an optimized cell line that will be employed for the analysis of virus collected with the developed instruments to enhance evaluation of infectivity. The core will validate the developed technologies for aerosol sampling, capture, isolation, culture, and analysis through a set of ferret studies before integration with the proposed U19 research projects, and will execute the required assays using clinical samples to support the goals of RP1 and RP2. The results of the ABTC research efforts will yield the instruments and technologies needed to enhance our understanding of influenza aerobiology, from the determination of critical source terms to the evaluation of infective particle distributions within the environment, supporting significant improvements to influenza transmission modeling, risk analysis, and mitigation, while making important contributions toward advancing our understanding of other respiratory viral pandemic threats.